See more : Meribank Biotech Co., Ltd (4724.TWO) Income Statement Analysis – Financial Results
Complete financial analysis of Genmab A/S (GNMSF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Genmab A/S, a leading company in the Biotechnology industry within the Healthcare sector.
- Havells India Limited (HAVELLS.BO) Income Statement Analysis – Financial Results
- Merchants Bancorp (MBINP) Income Statement Analysis – Financial Results
- Brenntag SE (BNR.DE) Income Statement Analysis – Financial Results
- Odd Burger Corporation (ODDAF) Income Statement Analysis – Financial Results
- CIMB Group Holdings Berhad (1023.KL) Income Statement Analysis – Financial Results
Genmab A/S (GNMSF)
About Genmab A/S
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37 for treating hematological malignancies. The company's also develops products, which is in Phase 2 comprise Teclistamab for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. In addition, it has approximately 20 active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with CureVac AG for the research and development of differentiated mRNA-based antibody products; AbbVie for the development of epcoritamab; and collaborations with BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 16.47B | 14.60B | 8.48B | 10.11B | 5.37B | 3.03B | 2.37B | 1.82B | 1.13B | 850.39M | 663.57M | 484.64M | 350.94M | 582.08M | 586.08M | 745.11M | 529.54M | 135.55M | 98.51M | 4.10M | 68.33M | 0.00 |
| Cost of Revenue | 226.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 532.51M | 582.51M | 0.00 | 48.81M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 16.25B | 14.60B | 8.48B | 10.11B | 5.37B | 3.03B | 2.37B | 1.82B | 1.13B | 850.39M | 663.57M | 484.64M | -181.57M | -435.00K | 586.08M | 696.30M | 529.54M | 135.55M | 98.51M | 4.10M | 68.33M | 0.00 |
| Gross Profit Ratio | 98.63% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | -51.74% | -0.07% | 100.00% | 93.45% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% |
| Research & Development | 7.63B | 5.56B | 4.18B | 3.14B | 2.39B | 1.43B | 874.28M | 660.88M | 487.66M | 505.68M | 527.58M | 536.70M | 532.51M | 0.00 | 935.36M | 1.42B | 618.50M | 359.95M | 304.10M | 373.33M | 345.98M | 396.23M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 661.00M | 342.00M | 213.70M | 146.99M | 102.41M | 91.22M | 79.53M | 66.74M | 64.61M | 67.85M | 160.25M | 148.75M | 143.53M | 38.59M | 37.11M | 38.04M | 72.04M | 64.55M | 86.85M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 3.30B | 2.68B | 1.28B | 661.00M | 342.00M | 213.70M | 146.99M | 102.41M | 91.22M | 79.53M | 66.74M | 64.61M | 67.85M | 160.25M | 148.75M | 143.53M | 38.59M | 37.11M | 38.04M | 72.04M | 64.55M | 86.85M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 10.93B | 8.24B | 5.46B | 3.80B | 2.73B | 1.64B | 1.02B | 763.29M | 402.66M | 585.21M | 594.32M | 601.32M | 67.85M | 160.25M | 1.08B | 1.35B | 966.67M | 607.76M | 526.43M | -437.17M | 410.54M | 440.17M |
| Cost & Expenses | 11.15B | 8.24B | 5.46B | 3.80B | 2.73B | 1.64B | 1.02B | 763.29M | 402.66M | 585.21M | 594.32M | 601.32M | 600.36M | 742.77M | 1.08B | 1.39B | 966.67M | 607.76M | 526.43M | -437.17M | 410.54M | 440.17M |
| Interest Income | 939.00M | 324.00M | 197.00M | 184.00M | 120.00M | 62.92M | 41.43M | 32.58M | 37.26M | 38.33M | 28.61M | 17.83M | 3.49M | 1.40M | 181.10M | 126.67M | 155.11M | 46.25M | 34.78M | 42.52M | 68.68M | 53.39M |
| Interest Expense | 27.00M | 21.00M | 13.00M | 10.00M | 7.00M | 417.00K | 2.80M | 213.00K | 118.00K | 4.05M | 3.33M | 2.72M | 43.09M | 39.65M | 25.05M | 220.83M | 1.15M | 1.03M | 1.35M | 68.58M | 83.71M | 100.37M |
| Depreciation & Amortization | 240.00M | 290.00M | 250.00M | 246.00M | 139.00M | 87.70M | 47.54M | 40.96M | 31.82M | 12.33M | 11.66M | 15.11M | 15.05M | 21.03M | 83.78M | 85.09M | 14.25M | 17.50M | 31.78M | 53.66M | 63.67M | 47.47M |
| EBITDA | 5.56B | 7.04B | 3.46B | 6.76B | 2.78B | 1.47B | 1.46B | 1.09B | 585.98M | 277.51M | 80.92M | -96.25M | -192.75M | -61.76M | -77.11M | -516.46M | -317.72M | -419.70M | -360.46M | 537.46M | 474.56M | 669.75M |
| EBITDA Ratio | 33.76% | 48.26% | 40.83% | 66.82% | 53.99% | 50.60% | 61.53% | 62.02% | 70.56% | 37.14% | 16.51% | -17.28% | -43.23% | -10.61% | -39.78% | -75.66% | -55.57% | -306.70% | -355.83% | 13,105.49% | 694.55% | 0.00% |
| Operating Income | 5.32B | 6.36B | 3.02B | 6.31B | 2.64B | 1.38B | 1.34B | 1.05B | 730.38M | 265.18M | 69.25M | -116.68M | -249.42M | -160.69M | -498.03M | -870.00M | -437.13M | -472.21M | -427.92M | 441.27M | -342.21M | -483.08M |
| Operating Income Ratio | 32.30% | 43.56% | 35.58% | 62.44% | 49.16% | 45.63% | 56.83% | 57.97% | 64.46% | 31.18% | 10.44% | -24.08% | -71.07% | -27.61% | -84.98% | -116.76% | -82.55% | -348.38% | -434.42% | 10,760.13% | -500.85% | 0.00% |
| Total Other Income/Expenses | 316.00M | 768.00M | 1.03B | -409.00M | 221.00M | 232.00M | -280.45M | 77.38M | 27.15M | 32.17M | -3.85M | 2.60M | 39.59M | 38.25M | 156.05M | -94.84M | 53.76M | 33.98M | 34.33M | -26.06M | -15.03M | 962.08M |
| Income Before Tax | 5.64B | 7.04B | 3.98B | 5.90B | 2.86B | 1.61B | 1.06B | 1.13B | 757.53M | 297.35M | 65.40M | -114.08M | -209.83M | -122.44M | -341.99M | -964.51M | -383.37M | -438.24M | -393.59M | 415.21M | 327.18M | 479.00M |
| Income Before Tax Ratio | 34.22% | 48.20% | 46.96% | 58.39% | 53.28% | 53.29% | 44.97% | 62.23% | 66.86% | 34.97% | 9.86% | -23.54% | -59.79% | -21.04% | -58.35% | -129.44% | -72.40% | -323.31% | -399.56% | 10,124.65% | 478.85% | 0.00% |
| Income Tax Expense | 1.29B | 1.51B | 975.00M | 1.15B | 693.00M | 139.83M | -39.83M | -56.86M | -5.99M | -3.95M | -4.75M | -2.63M | 5.92M | 20.87M | 5.91M | 583.00K | 128.62M | 38.99M | 45.64M | 872.94M | -66.00K | 326.00K |
| Net Income | 4.35B | 5.45B | 2.96B | 4.76B | 2.17B | 1.47B | 1.10B | 1.19B | 763.51M | 301.30M | 112.36M | -487.12M | -596.37M | -321.46M | -1.01B | -965.09M | -383.37M | -438.24M | -393.59M | -415.21M | -327.11M | -479.33M |
| Net Income Ratio | 26.42% | 37.36% | 34.86% | 47.06% | 40.37% | 48.66% | 46.67% | 65.36% | 67.39% | 35.43% | 16.93% | -100.51% | -169.94% | -55.23% | -172.46% | -129.52% | -72.40% | -323.31% | -399.56% | -10,124.65% | -478.75% | 0.00% |
| EPS | 66.02 | 83.38 | 46.00 | 73.00 | 34.40 | 24.03 | 18.14 | 19.83 | 13.05 | 5.35 | 2.20 | -10.58 | -13.28 | -7.16 | -22.51 | -21.62 | -8.72 | -11.26 | -12.59 | -15.69 | -14.33 | -21.46 |
| EPS Diluted | 66.02 | 82.59 | 45.54 | 72.22 | 34.04 | 23.72 | 17.77 | 19.22 | 12.56 | 5.26 | 2.16 | -10.58 | -13.28 | -7.16 | -22.51 | -21.62 | -8.72 | -11.26 | -12.59 | -15.69 | -14.33 | -21.46 |
| Weighted Avg Shares Out | 65.92M | 65.39M | 65.40M | 65.18M | 62.96M | 61.27M | 60.83M | 59.88M | 58.52M | 56.32M | 50.98M | 46.04M | 44.91M | 44.91M | 44.90M | 44.64M | 43.94M | 38.93M | 31.25M | 26.47M | 22.83M | 22.34M |
| Weighted Avg Shares Out (Dil) | 65.91M | 66.01M | 66.05M | 65.89M | 63.64M | 62.04M | 62.09M | 61.77M | 60.77M | 57.25M | 51.91M | 46.04M | 44.91M | 44.91M | 44.90M | 44.64M | 43.94M | 38.93M | 31.25M | 26.47M | 22.83M | 22.34M |
Genmab to Showcase Data in Various Patient Populations to be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting
Genmab Completes Acquisition of ProfoundBio
Genmab Completes Acquisition of ProfoundBio
Passing of Genmab A/S' Annual General Meeting
Genmab A/S (GMAB) Q4 2023 Earnings Call Transcript
5 Biotech Acquisition Targets To Accumulate In 2024
Genmab, Seagen say Tivdak cervical cancer trial met overall survival endpoint
Genmab and Seagen Announce That TIVDAK® (tisotumab vedotin-tftv) Met its Primary Endpoint of Improved Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared to Chemotherapy
Genmab A/S (GMAB) Q2 2023 Earnings Call Transcript
Genmab and AbbVie Announce Positive Topline Results from Phase 1/2 EPCORE™ NHL-1 Trial Evaluating Epcoritamab (DuoBody® CD3xCD20) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)
Source: https://incomestatements.info
Category: Stock Reports